News - Pharmaceuticals
Cystic fibrosis community celebrates positive recommendation for Trikafta listing

Pharma News: The Cystic Fibrosis (CF) community pleas have finally been answered.
The PBAC has made a positive recommendation for the listing of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of CF patients aged 12 years and older who have at least one F508del mutation in the CFTR gene (F/any population).
Jo Armstrong, CEO Cystic Fibrosis Australia, said “It is time to shout from the rooftops, the PBAC has recommended the inclusion of Trikafta on the PBS.
“We have been working on getting Trikafta over the line for years and we have a number of important allies to thank, not least are Minister Greg Hunt for his stalwart support of CFA and Jo Watson, the Deputy Chair of the PBAC and a great friend to our cause. We could not have done this without the support of the CF community who have been such strong advocated, providing their stories to the PBAC submissions and lobbying local Members of Parliament.”
A petition with 35,000 signatures calling for Trikafta to be subsidised under the PBS was presented to Federal Parliament in November 2021 by Labor MP and paediatrician Mike Freelander.
“Trikafta is a life-saving and life-changing treatment for people for people with cystic fibrosis,” Dr Freelander told parliament at the time. “We have seen people taken off the heart/lung transplant list. We’re seeing people’s lives saved.”
Vertex said in a company statement “We are pleased the PBAC has now recognised that all eligible CF patients should have access to Trikafta. However, it is disappointing that despite providing recent additional clinical data that supports the long-term effect of Trikafta and applying health economics methodology consistent with prior PBAC advice, the outcome has come at the expense of recognising the value of the medicine and its impact on patients.
“While there is still considerable work to do by all stakeholders in order to reach an agreement given the conditions related to the recommendation set out by the PBAC, we are committed to doing all we can to move the process along and have already initiated the next step.”
Ms Armstrong added “We urge the Department of Health and Vertex to move swiftly to ensure that the PBS listing happens as quickly as humanly possible.”
News - MedTech & Diagnostics
Roche unlocks new horizons for genomic research in Asia Pacific
Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]
MoreNews - Pharmaceuticals
‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly
The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]
MoreNews - MedTech & Diagnostics
More public hospitals turn to same-day hip and knee surgery, but key blind spots persist
Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]
MoreNews - Pharmaceuticals
TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning
The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]
More